Matinas BioPharma Holdings, Inc. (MTNB)
NYSEAMERICAN: MTNB · Real-Time Price · USD
0.561
+0.021 (3.80%)
Nov 21, 2024, 1:24 PM EST - Market open

Company Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.

The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.

It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium.

The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead’s remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations.

Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings logo
Country United States
Founded 2013
Industry Biotechnology
Sector Healthcare
Employees 32
CEO Jerome Jabbour

Contact Details

Address:
1545 Route 206 South, Suite 302
Bedminster, New Jersey 07921
United States
Phone 908 484 8805
Website matinasbiopharma.com

Stock Details

Ticker Symbol MTNB
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001582554
CUSIP Number 576810105
ISIN Number US5768101058
Employer ID 46-3011414
SIC Code 2834

Key Executives

Name Position
Jerome D. Jabbour J.D. Co-Founder, Chief Executive Officer, President and Director
Keith A. Kucinski CPA, M.B.A. Chief Financial Officer
Frank Calamusa Executive Director and Head of Manufacturing and Supply Chain

Latest SEC Filings

Date Type Title
Nov 13, 2024 10-Q Quarterly Report
Oct 31, 2024 8-K Current Report
Oct 25, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 24, 2024 8-K Current Report
Sep 3, 2024 8-K Current Report
Aug 28, 2024 8-K Current Report
Aug 20, 2024 8-K Current Report
Aug 14, 2024 8-K Current Report
Aug 14, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report